These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 1353452

  • 1. Subchronic treatment of rats with remoxipride fails to modify sigma binding sites in the brain.
    Ericson H, Ross SB.
    Eur J Pharmacol; 1992 Jun 05; 226(2):157-61. PubMed ID: 1353452
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the effects of haloperidol, remoxipride and raclopride on "pre"- and postsynaptic dopamine receptors in the rat brain.
    Magnusson O, Fowler CJ, Mohringe B, Wijkström A, Ogren SO.
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Apr 05; 337(4):379-84. PubMed ID: 2900472
    [Abstract] [Full Text] [Related]

  • 3. The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors.
    Ogren SO, Rosén L, Fuxe K.
    Neuroscience; 1994 Jul 05; 61(2):269-83. PubMed ID: 7969908
    [Abstract] [Full Text] [Related]

  • 4. Biochemical pharmacology of the atypical neuroleptic remoxipride.
    Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K.
    Acta Psychiatr Scand Suppl; 1990 Jul 05; 358():27-36. PubMed ID: 1978484
    [Abstract] [Full Text] [Related]

  • 5. Effects of chronic neuroleptic treatment on agonist affinity states of the dopamine-D2 receptor in the rat brain.
    Hall H, Sällemark M.
    Pharmacol Toxicol; 1987 May 05; 60(5):359-63. PubMed ID: 2886988
    [Abstract] [Full Text] [Related]

  • 6. Remoxipride shows low propensity to block functional striatal dopamine D2 receptors in vitro.
    Westlind-Danielsson A, Gustafsson K, Andersson I.
    Eur J Pharmacol; 1994 Dec 15; 288(1):89-95. PubMed ID: 7705472
    [Abstract] [Full Text] [Related]

  • 7. Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain.
    Köhler C, Radesäter AC, Karlsson-Boethius G, Bryske B, Widman M.
    J Neural Transm Gen Sect; 1992 Dec 15; 87(1):49-62. PubMed ID: 1531593
    [Abstract] [Full Text] [Related]

  • 8. Differential labeling of dopamine and sigma sites by [3H]nemonapride and [3H]raclopride in postmortem human brains.
    Tang SW, Helmeste DM, Fang H, Li M, Vu R, Bunney W, Potkin S, Jones EG.
    Brain Res; 1997 Aug 08; 765(1):7-12. PubMed ID: 9310388
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Heterogeneous binding of sigma radioligands in the rat brain and liver: possible relationship to subforms of cytochrome P-450.
    Ross SB.
    Pharmacol Toxicol; 1991 Apr 08; 68(4):293-301. PubMed ID: 1650944
    [Abstract] [Full Text] [Related]

  • 13. Comparison of [3H]YM-09151-2 with [3H]spiperone and [3H]raclopride for dopamine d-2 receptor binding to rat striatum.
    Terai M, Hidaka K, Nakamura Y.
    Eur J Pharmacol; 1989 Dec 07; 173(2-3):177-82. PubMed ID: 2576228
    [Abstract] [Full Text] [Related]

  • 14. Effects of remoxipride and some related new substituted salicylamides on rat brain receptors.
    Hall H, Sällemark M, Jerning E.
    Acta Pharmacol Toxicol (Copenh); 1986 Jan 07; 58(1):61-70. PubMed ID: 2869639
    [Abstract] [Full Text] [Related]

  • 15. Haloperidol treatment differentially regulates [3H]DTG and [3H](+)-3-PPP labeled sigma binding sites.
    Bailey MA, Karbon EW.
    Eur J Pharmacol; 1993 Aug 24; 240(2-3):243-50. PubMed ID: 7902283
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
    Ogren SO, Hall H, Köhler C, Magnusson O, Lindbom LO, Angeby K, Florvall L.
    Eur J Pharmacol; 1984 Jul 20; 102(3-4):459-74. PubMed ID: 6149133
    [Abstract] [Full Text] [Related]

  • 18. Neuroendocrinological and neurochemical effects of sigma ligands.
    Gudelsky GA, Nash JF.
    Neuropharmacology; 1992 Feb 20; 31(2):157-62. PubMed ID: 1348112
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.